Reportlinker Adds Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, June 22, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Trigeminal Neuralgia Therapeutics market. The report identifies the key trends shaping and driving the global Trigeminal Neuralgia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Trigeminal Neuralgia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Trigeminal Neuralgia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Trigeminal Neuralgia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Trigeminal Neuralgia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Trigeminal Neuralgia Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Trigeminal Neuralgia Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Trigeminal Neuralgia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Trigeminal Neuralgia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Trigeminal Neuralgia Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Trigeminal Neuralgia Therapeutics - Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 7
2.3 Etiology 7
2.4 Signs and Symptoms 7
2.5 Diagnosis 8
2.6 Referral Pathway 10
2.7 Treatment and Management Pattern 11
2.8 GlobalData Pipeline Report Guidance 12
3 Trigeminal Neuralgia Therapeutics - Market Characterization 13
3.1 Overview 13
3.2 TN Therapeutics Market Size (2005–2010) – Global 13
3.3 TN Therapeutics Market Forecast (2010–2017) – Global 14
3.4 TN Therapeutics Market Size (2005–2010) – The US 15
3.5 TN Therapeutics Market Forecast (2010–2017) – The US 16
3.6 TN Therapeutics Market Size (2005–2010) – France 17
3.7 TN Therapeutics Market Forecast (2010–2017) – France 18
3.8 TN Therapeutics Market Size (2005–2010) – Germany 19
3.9 TN Therapeutics Market Forecast (2010–2017) – Germany 20
3.10 TN Therapeutics Market Size (2005–2010) – Italy 21
3.11 TN Therapeutics Market Forecast (2010–2017) – Italy 22
3.12 TN Therapeutics Market Size (2005–2010) – Spain 23
3.13 TN Therapeutics Market Forecast (2010–2017) – Spain 24
3.14 TN Therapeutics Market Size (2005–2010) – The UK 25
3.15 TN Therapeutics Market Forecast (2010–2017) – The UK 26
3.16 TN Therapeutics Market Size (2005–2010) – Japan 27
3.17 TN Therapeutics Market Forecast (2010–2017) – Japan 28
3.18 Drivers and Barriers for the TN Therapeutics Market 29
3.18.1 Drivers for TN Therapeutics Market 29
3.18.2 Barriers for TN Therapeutics Market 29
3.19 Opportunity and Unmet Need Analysis 29
3.19.1 Opportunity and Unmet Need in the TN Market 29
3.20 Key Takeaway 30
4 Trigeminal Neuralgia Therapeutics - Competitive Assessment 31
4.1 Overview 31
4.2 Strategic Competitor Assessment 31
4.3 Product Profile for the Major Marketed Products in the TN Therapeutics 32
4.3.1 Tegretol 32
4.4 Key Takeaway 32
5 Trigeminal Neuralgia Therapeutics - Pipeline Assessment 33
5.1 Overview 33
5.2 Strategic Pipeline Assessment 33
5.3 TN Therapeutics Pipeline – Pipeline by Phases of Development 33
5.3.1 TN Therapeutics – Phase III Pipeline 33
5.4 Technology Trends Analytic Framework 34
5.5 TN Therapeutics Market – Pipeline by Mechanism of Action 35
5.6 TN Therapeutics – Promising Drugs under Clinical Development 35
5.7 Molecule Profiling for Promising Drugs Under Clinical Development 35
5.7.1 Lamictal 35
5.8 Key Takeaway 36
6 Trigeminal Neuralgia Therapeutics - Clinical Trials Mapping 37
6.1 Clinical Trials by Region/ Country 37
6.2 Clinical Trials by Phase 38
6.3 Clinical Trials by Trial Status 39
6.4 Sponsors 40
7 Trigeminal Neuralgia Therapeutics - Strategic Assessment 41
7.1 Key Events Impacting the Future Market 41
7.2 Implications for Future Market Competition 42
8 Trigeminal Neuralgia Therapeutics - Future Players 43
8.1 Introduction 43
8.2 Company Profiles 43
8.2.1 Novartis AG 43
9 TN Therapeutics - Licensing and Partnership Deals 46
10 Trigeminal Neuralgia Therapeutics - Appendix 47
10.1 Market Definitions 47
10.2 Abbreviations 47
10.3 Research Methodology 48
10.3.1 Coverage 48
10.3.2 Secondary Research 48
10.3.3 Forecasting 49
10.3.4 Primary Research 51
10.3.5 Expert Panel Validation 51
10.4 Contact Us 51
10.5 Disclaimer 51
10.6 Bibliography 52
List of Tables
1.1 List of Tables
Table 1: Differential Diagnosis of Trigeminal Neuralgia 8
Table 2: TN Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Table 3: TN Therapeutics Market, Global, Forecast ($m), 2010–2017 14
Table 4: TN Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Table 5: TN Therapeutics Market, The US, Forecast ($m), 2010–2017 16
Table 6: TN Therapeutics Market, France, Revenue ($m), 2005–2010 17
Table 7: TN Therapeutics Market, France, Forecasts ($m), 2010–2017 18
Table 8: TN Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Table 9: TN Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Table 10: TN Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Table 11: TN Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Table 12: TN Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 13: TN Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Table 14: TN Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Table 15: TN Therapeutics Market, The UK, Forecast ($m), 2010–2017 26
Table 16: TN Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 17: TN Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Table 18: TN Therapeutics Market, Phase III Clinical Pipeline, 2011 33
Table 19: TN Therapeutics Market, Most Promising Drugs Under Clinical Development, 2011 35
Table 20: TN Therapeutics Market, Number of Clinical Trials by Country, 2011 37
Table 21: TN Therapeutics Market, Number of Clinical Trials by Phase, 2011 38
Table 22: TN Therapeutics Market, Clinical Trials by Trial Status, 2011 39
Table 23: TN Therapeutics Market – Clinical Trials by Sponsors, 2011 40
Table 24: Novartis, TN Marketed product 44
Table 25: Novartis AG, Deals, 2010-2011 45
List of Figures
1.2 List of Figures
Figure 1: Trigeminal Nerve 6
Figure 2: Algorithm for the Diagnosis and Treatment of TN 9
Figure 3: Referral Pathway for TN 10
Figure 4: TN Therapeutics Market, Outcome of Surgical Treatments in TN (%) 11
Figure 5: TN Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Figure 6: TN Therapeutics Market, Global, Revenue ($m), 2010–2017 14
Figure 7: TN Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Figure 8: TN Therapeutics Market, The US, Forecast ($m), 2010–2017 16
Figure 9: TN Therapeutics Market, France, Revenue ($m), 2005–2010 17
Figure 10: TN Therapeutics Market, France, Forecast ($m), 2010–2017 18
Figure 11: TN Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Figure 12: TN Therapeutics Market, Germany, Forecast ($m), 2010–2017 20
Figure 13: TN Therapeutics Market, Italy, Revenue ($m), 2005–2010 21
Figure 14: TN Therapeutics Market, Italy, Forecast ($m), 2010–2017 22
Figure 15: TN Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 16: TN Therapeutics Market, Spain, Forecast ($m), 2010–2017 24
Figure 17: TN Therapeutics Market, The UK, Revenue ($m), 2005–2010 25
Figure 18: TN Therapeutics Market, The UK, Forecast ($m), 2010–2017 26
Figure 19: TN Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 20: TN Therapeutics Market, Japan, Forecast ($m), 2010–2017 28
Figure 21: Opportunity and Unmet Need in the TN Therapeutics Market, 2010 30
Figure 22: Strategic Competitor Assessment of the Marketed Products for TN, 2011 31
Figure 23: TN Therapeutics Market, Pipeline by Phase of Development (%), 2011 33
Figure 24: Technology Trends Analytic Framework of the TN Therapeutics Pipeline, 2011 34
Figure 25: Technology Trends Analytic Framework of the TN Therapeutics Pipeline, Description, 2011 34
Figure 26: TN Therapeutics Market, Pipeline by Mechanism of Action (%), 2011 35
Figure 27: TN Therapeutics Market, Number of Clinical Trials by Country, 2011 37
Figure 28: TN Therapeutics Market, Clinical Pipeline by Phase (%), 2011 38
Figure 29: TN Therapeutics Market, Clinical Trials by Trial Status (%), 2011 39
Figure 30: TN Therapeutics Market, Clinical Trials by Sponsors, 2011 40
Figure 31: TN Therapeutics, Global, Key Events Impacting the Future Market 41
Figure 32: Implications for Future Market Competition in the TN Therapeutics Market, 2011 42
Figure 33: TN Therapeutics Market, Clinical Pipeline by Company, 2011 43
Figure 34: GlobalData Market Forecasting Model 50
To order this report:
Pathology Industry: Trigeminal Neuralgia (TN) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article